Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial.

ABSTRACT:

Purpose

Selpercatinib, a highly selective, potent RET inhibitor with CNS activity, demonstrated sustained antitumor responses and intracranial activity in patients with RET-altered advanced non-small-cell lung cancer (NSCLC) in the global LIBRETTO-001 and Chinese LIBRETTO-321 trials. We report a prospective case series based on updated data from patients with brain metastases at baseline in LIBRETTO-321.

Materials and methods

We included patients with advanced NSCLC and brain metastasis with a centrally confirmed KIF5B/CCDC6/NCOA4-RET fusion. Patients with previously treated or untreated CNS metastases were included if asymptomatic or neurologically stable. Patients received oral selpercatinib 160 mg, twice daily, until progression. Objective syst

SUBMITTER: Cheng Y 

PROVIDER: S-EPMC10309543 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature